Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Potent Neutralization of Botulinum Neurotoxin/B by Synergistic Action of Antibodies Recognizing Protein and Ganglioside Receptor Binding Domain

  • Changchun Chen ,

    Contributed equally to this work with: Changchun Chen, Shuhui Wang, Huajing Wang

    Affiliation School of Pharmacy, The Center for Antibody Medicine of Ministry of Education, Shanghai Jiao Tong University, Shanghai, People's Republic of China

  • Shuhui Wang ,

    Contributed equally to this work with: Changchun Chen, Shuhui Wang, Huajing Wang

    Affiliation School of Pharmacy, The Center for Antibody Medicine of Ministry of Education, Shanghai Jiao Tong University, Shanghai, People's Republic of China

  • Huajing Wang ,

    Contributed equally to this work with: Changchun Chen, Shuhui Wang, Huajing Wang

    Affiliations International Joint Cancer Institute, The Second Military Medical University, Shanghai, People's Republic of China, National Engineering Research Center for Antibody Medicine, State Key Laboratory of Antibody Medicine and Targeting Therapy and Shanghai Key Laboratory of Cell Engineering, Shanghai, People's Republic of China

  • Xiaoyan Mao,

    Affiliation Lanzhou Institute of Biological Products, Lanzhou, Gansu, People's Republic of China

  • Tiancheng Zhang,

    Affiliations International Joint Cancer Institute, The Second Military Medical University, Shanghai, People's Republic of China, National Engineering Research Center for Antibody Medicine, State Key Laboratory of Antibody Medicine and Targeting Therapy and Shanghai Key Laboratory of Cell Engineering, Shanghai, People's Republic of China

  • Guanghui Ji,

    Affiliations International Joint Cancer Institute, The Second Military Medical University, Shanghai, People's Republic of China, National Engineering Research Center for Antibody Medicine, State Key Laboratory of Antibody Medicine and Targeting Therapy and Shanghai Key Laboratory of Cell Engineering, Shanghai, People's Republic of China

  • Xin Shi,

    Affiliations International Joint Cancer Institute, The Second Military Medical University, Shanghai, People's Republic of China, National Engineering Research Center for Antibody Medicine, State Key Laboratory of Antibody Medicine and Targeting Therapy and Shanghai Key Laboratory of Cell Engineering, Shanghai, People's Republic of China

  • Tian Xia,

    Affiliations International Joint Cancer Institute, The Second Military Medical University, Shanghai, People's Republic of China, National Engineering Research Center for Antibody Medicine, State Key Laboratory of Antibody Medicine and Targeting Therapy and Shanghai Key Laboratory of Cell Engineering, Shanghai, People's Republic of China

  • Weijia Lu,

    Affiliation Lanzhou Institute of Biological Products, Lanzhou, Gansu, People's Republic of China

  • Dapeng Zhang,

    Affiliations International Joint Cancer Institute, The Second Military Medical University, Shanghai, People's Republic of China, National Engineering Research Center for Antibody Medicine, State Key Laboratory of Antibody Medicine and Targeting Therapy and Shanghai Key Laboratory of Cell Engineering, Shanghai, People's Republic of China

  • Jianxin Dai ,

    jxdai@smmu.edu.cn (JXD); yjguo@smmu.edu.cn (YJG)

    Affiliations International Joint Cancer Institute, The Second Military Medical University, Shanghai, People's Republic of China, National Engineering Research Center for Antibody Medicine, State Key Laboratory of Antibody Medicine and Targeting Therapy and Shanghai Key Laboratory of Cell Engineering, Shanghai, People's Republic of China, PLA General Hospital Cancer Center, Beijing, People's Republic of China

  • Yajun Guo

    jxdai@smmu.edu.cn (JXD); yjguo@smmu.edu.cn (YJG)

    Affiliations International Joint Cancer Institute, The Second Military Medical University, Shanghai, People's Republic of China, National Engineering Research Center for Antibody Medicine, State Key Laboratory of Antibody Medicine and Targeting Therapy and Shanghai Key Laboratory of Cell Engineering, Shanghai, People's Republic of China, PLA General Hospital Cancer Center, Beijing, People's Republic of China

Viewed

Cited

Saved

Discussed

Powered by Altmetric
Questions or concerns about usage data? Please let us know.